Klausner Richard 4

What Happened
Richard Klausner, a director of Parabilis Medicines, was granted an award on 2026-06-09 covering 20,215 shares (reported as a derivative acquisition; price listed as $0.00). This filing reports a grant of an option-like award rather than a purchase or sale — there was no cash changing hands at grant and no immediate exercise or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-11 (timely; within the typical two-business-day filing window).
• Transaction type: Award/Grant of a derivative (reported code A); 20,215 underlying shares; reported price $0.00.
• Shares owned after transaction: Not specified in the excerpt provided; see the full Form 4 for total beneficial ownership.
• Footnote: The award vests and becomes exercisable in full on the earlier of (i) June 9, 2027 or (ii) the issuer's next annual meeting of stockholders, provided the reporting person remains in service on the vesting date.

Context
This is a compensation-related award to a board member (a common corporate practice) rather than a market purchase or sale. Because the award vests in the future, it does not represent immediately tradable shares; it becomes exercisable only if vesting conditions are met. Grants like this are routine and reflect director compensation, not direct buy/sell sentiment.